Blood ammonia test method

By adding inhibitors such as sodium acetamipridate and GGsTop to the blood ammonia assay method, the interference of plasma lactate dehydrogenase and γ-glutamyl transferase on blood ammonia measurement was solved, thus achieving accuracy and repeatability of blood ammonia measurement.

CN117805044BActive Publication Date: 2026-11-17TIANJIN BAODI HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410182921.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-19
Publication Date
2026-11-17
Estimated Expiration
2044-02-19

AI Technical Summary

Technical Problem

Interference from lactate dehydrogenase and gamma-glutamyl transferase in plasma affects the accuracy of blood ammonia test results, especially when the levels of lactate dehydrogenase and gamma-glutamyl transferase are high, and existing technologies are unable to effectively eliminate the interference.

Method used

In the blood ammonia assay, sodium acetamipate (H2NCOCOONa) is used as a lactate dehydrogenase inhibitor and GGsTop as a gamma-glutamyl transferase inhibitor. Combined with Tris buffer, EDTA, α-ketoglutarate, NADH and other components, the activities of lactate dehydrogenase and gamma-glutamyl transferase are inhibited respectively through stepwise reactions of reagent I and reagent II, ensuring the accuracy of ammonia assay results.

Benefits of technology

It effectively eliminates the interference of lactate dehydrogenase and γ-glutamyl transferase, improves the accuracy and repeatability of blood ammonia measurement, and ensures the reliability of the measurement results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117805044B_ABST
    Figure CN117805044B_ABST
Patent Text Reader

Abstract

This invention relates to the field of blood testing technology, and more particularly to a method for measuring blood ammonia by eliminating interference from lactate dehydrogenase and gamma-glutamyl transferase in plasma. The technical solution is as follows: Reagent I, Tris buffer, contains lactate dehydrogenase inhibitors, gamma-glutamyl transferase inhibitors, EDTA, α-ketoglutarate, and NADH; Reagent II contains only glutamate dehydrogenase and ADP. When plasma is added to Reagent I, due to H2NCOCOO... ‑ GGsTop inhibited LDH activity, preventing it from consuming NADH. It also inhibited the γ-glutamyl transferase-catalyzed reaction of glutamate to NH3. Upon the addition of reagent II, in the presence of sufficient α-ketoglutarate and NADH, plasma ammonia was converted to glutamate and NAD3 by glutamate dehydrogenase. + The instrument detects at a wavelength of 340 nm. The absorbance produced by the reaction of reagent I is used as a blank, and the content of hematoxylin and cyanide is calculated from the absorbance produced by the reaction of reagent II.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of blood testing technology, and more particularly to a method for measuring blood ammonia by eliminating interference from lactate dehydrogenase and γ-glutamyl transferase in plasma. Background Technology

[0002] Ammonia is a harmful substance to the human body, and the liver is its main metabolic site. Normal human blood contains trace amounts of free ammonia. Endogenous ammonia is produced from amino acids during protein metabolism, which undergo deamination; this is the main source of ammonia in the blood. Exogenous ammonia is produced by the decomposition of protein-rich foods by bacteria in the intestines. Ammonia from organs such as the brain and kidneys reacts with glutamate to form glutamine, which is then transported to the liver. In the liver, it is converted into urea or other nitrogenous compounds and excreted by the kidneys, or as ammonium salts in the urine. Increased sources and decreased elimination of ammonia can both lead to elevated blood ammonia levels. Elevated blood ammonia can affect neuronal function and nerve cell metabolism. Common conditions with elevated blood ammonia include hepatic encephalopathy, hepatic coma, cirrhosis, and some congenital hyperammonemias. In severe liver disease, ammonia cannot be cleared from the circulation, causing elevated blood ammonia levels. Excessive ammonia can disrupt the energy metabolism of brain cells, and insufficient energy supply to brain tissue affects the production and balance of neurotransmitters in the central nervous system. In severe cases, it can lead to brain cell poisoning. Therefore, paying attention to blood ammonia testing and taking timely treatment measures can improve the patient's quality of life and reduce mortality, which is of great clinical significance.

[0003] Clinical laboratory methods for detecting blood ammonia include: (1) Direct colorimetric assay: 2 ml of venous blood is collected at the bedside, protein is precipitated with tungstic acid, and then phenol-hypochlorite is used for colorimetric assay. The ammonia content is calculated with reference to the standard. (2) Glutamate dehydrogenase (GLDH) method: In the presence of sufficient α-ketoglutarate and NADH, ammonia in plasma is converted into glutamate by glutamate dehydrogenase and consumes NADH. The production of NADH is directly proportional to the plasma ammonia concentration. (3) Ion exchange method: Ammonia in protein-free plasma samples is first adsorbed by cation exchange resin and then separated. The ammonia content is determined by phenol-hypochlorite colorimetric reaction. (4) Ammonia electrode method: The ammonia electrode method has high selectivity, so this type of method has good specificity and high accuracy. However, it has poor durability, and the electrode stability is affected by various factors such as temperature, osmotic pressure, and medium. The commonly used method in clinical laboratories is the glutamate dehydrogenase method. However, the 4th edition of the "National Clinical Laboratory Operation Procedures" reports the following problems with this method: Lactate dehydrogenase (LDH) in plasma can also utilize NADH; high levels of gamma-glutamyl transferase cause the breakdown of glutamate to produce NH3, which affects the accuracy of plasma ammonia measurement results. In particular, diseases with elevated lactate dehydrogenase and gamma-glutamyl transferase levels seriously affect the results of blood ammonia measurement.

[0004] Gamma-glutamyl transferase (GGT) is a membrane-bound glycoprotein with a molecular weight of 76-87 kDa in humans. Its main function is to participate in protein metabolism, and it is primarily distributed in solid organs such as the liver, kidneys, and pancreas. In normal individuals, serum GGT mainly originates from the liver, where it is primarily confined to bile capillaries and hepatocyte microsomes. GGT plays a crucial role in the metabolism of plasma glutathione (GSH) and its S-conjugates, cleaving the γ-glutamyl bond through hydrolysis and / or peptide transfer. GGsTop is a novel, highly selective, and irreversible inhibitor of gamma-glutamyl transferase (GGT) with a Km value of 0.17 mM, a molecular weight of 331.26, and the molecular formula C0.05. 13 H 18 N07P, with the structural formula (S)-2-amino-4-((S)-(3-(carboxymethyl)phenoxy)(methoxy)phosphorylated butyric acid), has a solubility greater than 10 mM.

[0005] Lactate dehydrogenase uses pyruvate (molecular formula CH3COCOOH) and NADH as its substrates. H2NCOCOOH is formed by replacing the -CH3 group in the pyruvate molecule with an acetaminophen or oxalic acid. This is due to the substitution of the -CH3 group with the equivalent -NH2 group in the pyruvate molecule. This change from -CH3 to -NH2 disrupts the pyruvate-induced fit, leading to inhibition. This results in a significant alteration in the charge distribution between the substrate and inhibitor, but without a substantial structural change. The large change in charge distribution and the relatively good structural consistency lead to… Inhibitors can more easily enter the enzyme's active site and bind to the enzyme than the substrate. Once inside the active site, the inhibitor, through induced fit, alters part of the enzyme's active site structure, significantly impacting the reaction. The stable conformation of the inhibitor and substrate is structurally very similar, preventing lactate dehydrogenase from effectively recognizing the substrate. The net charge of each atom in the inhibitor makes it easier for the inhibitor to bind to the enzyme's active site. The inhibitor reduces the space of the enzyme's active site through induced fit; therefore, acetamipelone inhibits lactate dehydrogenase much more effectively than oxalate. White et al.'s experiments confirmed this. - It is an effective competitive inhibitor of LDH, and LDH·H2N-CO-COO was prepared. - ·NADH ternary complex crystal.

[0006] In existing technologies, to eliminate the interference of endogenous lactate dehydrogenase on blood ammonia measurement, companies such as Beijing Leadman Biochemical Co., Ltd. and Shanghai Fosun Changzheng Co., Ltd. often add a high concentration of LDH to reagent I. In the first step of the reaction, LDH catalyzes the reaction of pyruvate and NADH. After adding reagent II, in the presence of sufficient α-ketoglutarate and NADH, ammonia in the plasma is converted into glutamate and NAD through the action of glutamate dehydrogenase. + The instrument detects the ammonia content at a wavelength of 340 nm, consuming NADH. The absorbance produced by the reaction of reagent I is used as a blank, and the absorbance produced by the reaction of reagent II is used to calculate the ammonia content. Summary of the Invention

[0007] The purpose of this invention is to provide a method for measuring blood ammonia without interference from lactate dehydrogenase and γ-glutamyl transferase in plasma. Lactate dehydrogenase uses pyruvate and NADH as substrates, and H2NCOCOONa and H2NCOCOO are added to the kit. - The -H2N group replaces the -CH3 group in the pyruvate molecule, disrupting the binding of lactate dehydrogenase with pyruvate and altering part of the enzyme's active site structure to some extent. The advantage of the net charge of each atom of the inhibitor makes it easier for the inhibitor to bind to the enzyme's active site, causing lactate dehydrogenase to be unable to effectively recognize pyruvate, thereby inhibiting the lactate dehydrogenase interference reaction. GGsTop is a novel, highly selective, and irreversible γ-glutamyl transferase (GGT) inhibitor that can inhibit γ-glutamyl transferase from glutamate to NH3 without affecting the accuracy of plasma ammonia measurement results.

[0008] The technical solution of this invention is as follows: Reagent I, Tris buffer, contains lactate dehydrogenase inhibitor, γ-glutamyl transpeptidase inhibitor, EDTA, α-ketoglutarate, and NADH; Reagent II contains only glutamate dehydrogenase and ADP. When plasma is added to Reagent I, it is reacted with H2NCOCOO. - Inhibiting LDH activity prevents it from consuming NADH. GGsTop inhibits the γ-glutamyl transferase-catalyzed reaction of glutamate to NH3. When reagent II is added, plasma ammonia, in the presence of sufficient α-ketoglutarate and NADH, is converted to glutamate and NAD by glutamate dehydrogenase. + The instrument detects at a wavelength of 340nm. The absorbance generated by the reaction of reagent I is used as a blank. The content of blood ammonia is calculated from the absorbance generated by the reaction of reagent II. The interference of lactate dehydrogenase and γ-glutamyl transferase is eliminated. The following are the reaction equations for ammonia determination (1), lactate dehydrogenase interference reaction (2), and γ-glutamyl transferase interference reaction (3).

[0009]

[0010]

[0011] Attached image description:

[0012] Figure 1 Real-time reaction graph of blood ammonia measurement. Detailed implementation method:

[0013] Example 1

[0014] 1. Preparation of Blood Ammonia Assay Kit: Reagent I: Tris buffer 50 mmol / L pH 8.0 containing 16.0 mmol / L α-ketoglutarate, 0.16 mmol / L NADH, 0.4 mmol / L H2NCOCOONa, 0.5 mmol / L GGsTop, 2.0 mmol / L EDTA, and 200 μL Proclin-300 preservative; Reagent II: Tris buffer 50 mmol / L pH 8.0 containing 20.0 KU / L GLDH, 0.5 mmol / L ADP, and 200 μL Proclin-300 preservative.

[0015] Among them, sodium acetate (H2NCOCOONa) is a lactate dehydrogenase inhibitor, GGsTop is a gamma-glutamyl transferase inhibitor, disodium ethylenediaminetetraacetate (EDTA) is a calcium ion interference eliminator, Proclin-300 is a highly effective preservative, and adenosine diphosphate (ADP) is an activator of GLDH and can stabilize the conformation of the enzyme.

[0016] Example 2

[0017] Taking the Beckman AU5800 fully automated biochemical analyzer as an example, the measurement parameters of this invention are as follows:

[0018]

[0019] OD 氨 =OD2-OD1×[(SV+R1V1) / (SV+R1V1+R2V2)]

[0020] Ammonia concentration = F × OD 氨

[0021] Among them OD 氨 OD1 is the actual absorbance produced in the ammonia determination reaction, OD2 is the absorbance measured after adding reagent I to the sample and reacting, OD3 is the absorbance measured after adding reagent II to the sample and reacting, SV is the volume of plasma, R1V1 is the volume of reagent I, and R2V2 is the volume of reagent II. F is the correction factor. Since this method is a negative reaction, the correction factor and the absorbance OD2 produced by ammonia are considered. 氨 All are negative values.

[0022] Example 3

[0023] Experimental performance parameters of this invention: normal reference value ≤15μmol / L; blank absorbance >0.55ABS (0.5cm optical path, 340nm, 37℃); linearity: 0.21~50μmol / L; intra-batch precision <8%; inter-batch precision <15%; recovery rate between 95% and 105%. Lactate dehydrogenase <1600U / L and γ-glutamyl transferase <800U / L showed no significant interference. Correlation analysis with Beijing Leadman Biochemical Co., Ltd.: Y 本发明 =1.021X 利德曼 -0.1535; R 2 =0.9910.

Claims

1. A method for measuring blood ammonia without interference from lactate dehydrogenase and gamma-glutamyl transferase in plasma, comprising the following technical solution: Reagent I, Tris buffer, contains lactate dehydrogenase (LDH) inhibitor, gamma-glutamyl transferase inhibitor, EDTA, α-ketoglutarate, and NADH; Reagent II contains glutamate dehydrogenase and adenosine diphosphate (ADP). When plasma is added to Reagent I, the lactate dehydrogenase inhibitor inhibits LDH activity, preventing it from consuming NADH; GGsTop inhibits the reaction catalyzed by gamma-glutamyl transferase to produce NH3 from glutamate. When Reagent II is added, in the presence of sufficient α-ketoglutarate and NADH, ammonia in the plasma is converted into glutamate and NAD through the action of glutamate dehydrogenase. + The instrument detects at a wavelength of 340 nm. The absorbance produced by the reaction of reagent I is used as a blank, and the content of hematoxylin and cyanide is calculated from the absorbance produced by the reaction of reagent II.

2. The method for measuring blood ammonia according to claim 1, which eliminates interference from lactate dehydrogenase and γ-glutamyl transferase in plasma, is characterized in that... Blood Ammonia Assay Kit Reagent I: Tris buffer 50 mmol / L pH 8.0 contains α-ketoglutarate 12.0–24.0 mmol / L, NADH 0.12–0.20 mmol / L, H2NCOCOONa 0.2–0.6 mmol / L, GGsTop 0.1–0.9 mmol / L, EDTA 1.0–3.0 mmol / L, and Proclin-300 preservative 100–300 µL; Reagent II: Tris buffer 50 mmol / L pH 8.0 contains GLDH > 20.0 KU / L, ADP 0.3–0.7 mmol / L, and Proclin-300 preservative 100–300 µL.

3. The method for measuring blood ammonia according to claim 2, which eliminates interference from lactate dehydrogenase and γ-glutamyl transferase in plasma, is characterized in that... Sodium acetate (H2NCOCOONa) is a lactate dehydrogenase inhibitor, GGsTop is a gamma-glutamyl transferase inhibitor, disodium ethylenediaminetetraacetate (EDTA) is a calcium ion interference eliminator, Proclin-300 is a highly effective preservative, and adenosine diphosphate (ADP) is an activator of GLDH and can stabilize the conformation of the enzyme.

4. The method for measuring blood ammonia according to claim 2, which eliminates interference from lactate dehydrogenase and γ-glutamyl transferase in plasma, is characterized in that... The pH of the Tris buffer in Reagent I and Reagent II is 7.8 ± 8.

2.

5. The method for measuring blood ammonia according to claim 2, characterized in that it eliminates interference from lactate dehydrogenase and γ-glutamyl transferase in plasma. The measured volume ratio was: sample: reagent I: reagent II = 1:5~15:1.5~2.5.

Citation Information

Patent Citations

  • Stable liquid detection kit

    CN114354524A

  • Determination of blood ammonia content and blood ammonia diagnostic reagent kit

    CN1778946A